Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Avi S. Retter"'
Publikováno v:
Infectious Diseases in Obstetrics and Gynecology, Vol 11, Iss 2, Pp 109-115 (2003)
Background: We describe a case and review ten other instances of group B streptococcal endocarditis in the setting of obstetric and gynecologic practice reported since the last review in 1985.
Externí odkaz:
https://doaj.org/article/17a6b591b41a4cc2968aabdbdd996e71
Autor:
Benjamin A. Gartrell, Alexander G Vandell, Gerald H. Sokol, Mack Roach, Wen-Tien Chen, G. Del Priore, Avi S. Retter, Howard I. Scher
Publikováno v:
Annals of Oncology. 30:v342
Background Androgen deprivation therapy (ADT) is standard treatment for rising PSA with/without circulating tumor cells (CTCs) but adverse events (AEs) limit patient acceptance. We report results of SM-88 (D,L-alpha-metyrosine; racemetyrosine [USAN])
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab447710d7a8ac556dc0bc3fb4d89e78
https://doi.org/10.1093/annonc/mdz248.030
https://doi.org/10.1093/annonc/mdz248.030
Autor:
Benjamin A. Gartrell, Giuseppe Del Priore, Gerald H. Sokol, Avi S. Retter, Alexander G Vandell, Mack Roach
Publikováno v:
Journal of Clinical Oncology. 37:79-79
79 Background: Treatment for rising PSA non-metastatic prostate cancer (nmPC) includes multifaceted hormone therapies (HT) associated with increasing related toxicity; in aggregate the risk benefit ratio is not ideal. We report on the use before HT,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea7e07e7250c9ee85e7e3ab4c0f6d6c4
https://doi.org/10.1200/jco.2019.37.7_suppl.79
https://doi.org/10.1200/jco.2019.37.7_suppl.79
Autor:
Wen-Tien Chen, Gerald H. Sokol, Alexander G Vandell, Mack Roach, Benjamin A. Gartrell, Avi S. Retter, Giuseppe Del Priore
Publikováno v:
Journal of Clinical Oncology. 37:83-83
83 Background: Absolute PSA change is an imperfect surrogate of clinical benefit; CTCs and PSA doubling time (DT) may also be used as a surrogate of progression (PD). Hormone therapy (HT) often leads to a rapid decline in PSA, however non-HT may be e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9a261437629c65752701b021ec51c7c
https://doi.org/10.1200/jco.2019.37.7_suppl.83
https://doi.org/10.1200/jco.2019.37.7_suppl.83
Autor:
Giuseppe Del Priore, Zachary Gostout, Patricia Zawisny, Steve Hoffman, Gerald H. Sokol, Mack Roach, Avi S. Retter
Publikováno v:
Journal of Clinical Oncology. 36:175-175
175 Background: Despite toxicity and no clear survival benefit, non-metastatic recurrent prostate cancer (nmPC) is typically treated with androgen deprivation therapy (ADT). SM88 is a relatively non-toxic novel combination therapy (amino acid analogu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f86299dc68ccf8c9c6d47388afe3272c
https://doi.org/10.1200/jco.2018.36.6_suppl.175
https://doi.org/10.1200/jco.2018.36.6_suppl.175
Autor:
Avi S. Retter
Publikováno v:
Heart Disease. 4:387-391
Malignant pericardial disease is a serious and common problem seen in patients with cancer. It is usually due to metastatic spread of the underlying malignancy or a complication of radiation therapy. The patient may have a mild, subtle presentation,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6adf9116ca3cfa14933b9e31cdfc364e
https://doi.org/10.1097/00132580-200211000-00008
https://doi.org/10.1097/00132580-200211000-00008
Autor:
Steve Hoffman, Gerald H. Sokol, Karen E. Hoffman, Giuseppe Del Priore, Avi S. Retter, John Rothman
Publikováno v:
Journal of Clinical Oncology. 35:e14061-e14061
e14061 Background: SM88 is a combination of tyrosine isomers ( TI) and repurposed drugs (modulators of CYP3A4, mTOR, and oxidative stress). This regimen has previously reported non-toxic activity in cancers including prostate (PC) ( J Clin Oncol 2013
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::18ed9a430f852118eaaf76cb8fc679b3
https://doi.org/10.1200/jco.2017.35.15_suppl.e14061
https://doi.org/10.1200/jco.2017.35.15_suppl.e14061
Publikováno v:
Clinical Infectious Diseases. 37:e88-e90
Intravenous immunoglobulin (IVIG) with high titers to West Nile virus was used as an adjuvant therapy for a patient with West Nile virus encephalitis that did not respond to supportive care. We present this case report and review the evidence support
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f9f24f2d7fc5c246c7ed94efe2c4051
https://doi.org/10.1086/377172
https://doi.org/10.1086/377172
Autor:
Clara C. Chen, John Wright, Tristan M. Sissung, James L. Gulley, Phil Arlen, Haiqing Li, Avi S. Retter, William D. Figg, Kathy Fedenko, Howard L. Parnes, Seth M. Steinberg, Elizabeth C. Jones, William L. Dahut, L. Latham, Shenhong Wu
Publikováno v:
BJU international. 99(5)
OBJECTIVE To evaluate the combination of docetaxel plus estramustine (which prolongs survival in patients with androgen-independent prostate cancer, AIPC), and thalidomide (that also adds to docetaxel activity), both pre-clinically and clinically in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c39eefc4d8ab0ab98d532ec3d39be662
https://pubmed.ncbi.nlm.nih.gov/17437439
https://pubmed.ncbi.nlm.nih.gov/17437439
Publikováno v:
Clinical prostate cancer. 2(3)
Metastatic prostate cancer is one of the leading causes of cancer death in men. Although Initialsly responsive to hormone therapy, it eventually progresses in almost all patients. For this reason, there has been a search for novel agents to use in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::338de809686edb7760a3be9907b64455
https://pubmed.ncbi.nlm.nih.gov/15040858
https://pubmed.ncbi.nlm.nih.gov/15040858